F-group (family)
132.1.1.1 PP-binding
Ligands and drugs
2,710
Member domains
929
with ligand contacts (≤ 4 Å)
34.3% of members
657
with DrugDomain annotations
24.2% of members
192
with a DrugBank compound
7.1% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 132.1.1.1 belongs to X-group 132 ACP-like, which binds 5.1 ligand superclasses per 20 proteins, narrower than 81% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03912 | PNS | D-pantetheine 4'-phosphate | 150 |
| DB04450 | HTG | Heptyl 1-Thiohexopyranoside | 12 |
| DB01992 | COA | Coenzyme A | 4 |
| DB03461 | NAP | Nicotinamide adenine dinucleotide phosphate | 2 |
| DB08404 | PM4 | S-(2-{[N-(2-HYDROXY-4-{[HYDROXY(OXIDO)PHOSPHINO]OXY}-3,3-DIMETHYLBUTANOYL)-BETA-ALANYL]AMINO}ETHYL) HEXANETHIOATE | 2 |
| DB08405 | PM5 | S-(2-{[N-(2-HYDROXY-4-{[HYDROXY(OXIDO)PHOSPHINO]OXY}-3,3-DIMETHYLBUTANOYL)-BETA-ALANYL]AMINO}ETHYL) HEPTANETHIOATE | 2 |
| DB08585 | SXH | S-[2-({N-[(2S)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] hexanethioate | 2 |
| DB08586 | SXO | S-[2-({N-[(2S)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] octanethioate | 2 |
| DB00116 | — | — | 1 |
| DB00157 | — | NADH | 1 |
| DB00974 | EDT | Edetic acid | 1 |
| DB03193 | STE | Stearic acid | 1 |
| DB03345 | BME | Mercaptoethanol | 1 |
| DB03600 | DKA | Capric acid | 1 |
| DB04377 | MAH | Meglutol | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| EHZ | ~{S}-[2-[3-[[(2~{R})-3,3-dimethyl-2-oxidanyl-4-phosphonooxy-butanoyl]amino]propanoylamino]ethyl] (3~{S})-3-oxidanyltetradecanethioate | 188 |
| PNS | 4'-PHOSPHOPANTETHEINE | 183 |
| ZMP | S-[2-({N-[(2S)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] tetradecanethioate | 172 |
| 8Q1 | S-[2-({N-[(2R)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] dodecanethioate | 163 |
| PN7 | N~3~-[(2S)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-N-(2-sulfanylethyl)-beta-alaninamide | 22 |
| ZNmetal | ZINC ION | 16 |
| 9EF | N-[2-(acetylamino)ethyl]-N~3~-[(2R)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alaninamide | 13 |
| HTG | heptyl 1-thio-beta-D-glucopyranoside | 12 |
| PM8 | S-(2-{[N-(2-HYDROXY-4-{[HYDROXY(OXIDO)PHOSPHINO]OXY}-3,3-DIMETHYLBUTANOYL)-BETA-ALANYL]AMINO}ETHYL) DECANETHIOATE | 12 |
| IOD | IODIDE ION | 7 |
| 1F7 | S-[2-({N-[(2S)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] (3R)-3-hydroxytetradecanethioate | 6 |
| CDL | CARDIOLIPIN | 6 |
| OLA | OLEIC ACID | 6 |
| XLN | N~3~-{(2R)-4-[(dihydroxyphosphanyl)oxy]-2-hydroxy-3,3-dimethylbutanoyl}-N-(3-{[(1Z)-pent-1-en-1-yl]sulfonyl}propyl)-beta-alaninamide | 6 |
| MRJ | N-[2-(dodecanoylamino)ethyl]-N~3~-[(2R)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alaninamide | 5 |
| NAmetal | SODIUM ION | 5 |
| 868 | S-[2-[3-[[(2S)-3,3-dimethyl-2-oxidanyl-4-phosphonooxy-butanoyl]amino]propanoylamino]ethyl] (2R)-2-azanylpropanethioate | 4 |
| A1AN1 | (7S,10aR)-1-methyl-4-{4-[(5R)-1,1,5-trihydroxy-4,4-dimethyl-1,6,11-trioxo-2-oxa-7,10-diaza-1lambda~5~-phosphadodecan-12-yl]phenyl}-3,5,6,7,8,9,10,10a-octahydrocycloocta[d]pyridazin-7-yl [2-({N-[(2R)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl]carbamate | 4 |
| COA | COENZYME A | 4 |
| KH4 | S-[2-({N-[(2R)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] 1H-imidazole-4-carbothioate | 4 |